Hanall Biopharma Co., Ltd. (KRX:009420)

Hanall Biopharma Revenue

Hanall Biopharma had revenue of 44.28B KRW in the quarter ending June 30, 2026, with 8.83% growth. This brings the company's total for the last twelve months to 162.66B, up 8.38% year-over-year. In the year 2025, Hanall Biopharma had annual revenue of 155.18B with 11.69% growth. That makes Hanall Biopharma the 21,177th largest company in the world by revenue and 1,151st in South Korea.

• Revenue (ttm): 162.66B
• Revenue Growth: +8.38%
• P/S Ratio: 11.96
• Revenue / Employee: 566.76M
• Employees: 287
• Market Cap: 1.96T

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• South Korea 147.39B 95.0%
• Export 7.80B 5.0%

Fiscal year ended Dec 31, 2025 See the full Hanall Biopharma breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	155.18B	16.24B	11.69%
Dec 31, 2024	138.94B	4.03B	2.99%
Dec 31, 2023	134.91B	24.91B	22.65%
Dec 31, 2022	110.00B	8.40B	8.27%
Dec 31, 2021	101.59B	12.99B	14.66%

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error